AP298A - Herpes simplex vaccine comprising HSV Glycoprotein gD and 3 deacylated mono-phosphoryl lipid A. - Google Patents

Herpes simplex vaccine comprising HSV Glycoprotein gD and 3 deacylated mono-phosphoryl lipid A. Download PDF

Info

Publication number: AP298A
Authority: AP; ARIPO
Prior art keywords: rgd2t; alum; hsv; mpl; glycoprotein
Prior art date: 1991-03-21

Application number

APAP/P/1992/000368A

Other languages

English (en)

Other versions

AP9200368A0 (en

Inventor

Myriam Francotte

Jean Paul Prieels

Moncef Slaqui

Nathalie Marie-Josephe Claude Garcon-Johnson

Original Assignee

Smithkline Biologicals S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-03-21

Filing date

1992-03-20

Publication date

1994-01-14

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10691946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP298(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-03-20 Application filed by Smithkline Biologicals S A filed Critical Smithkline Biologicals S A

1992-04-30 Publication of AP9200368A0 publication Critical patent/AP9200368A0/xx

1994-01-14 Application granted granted Critical

1994-01-14 Publication of AP298A publication Critical patent/AP298A/en

Links

229940035032 monophosphoryl lipid a Drugs 0.000 title claims abstract description 10
108090000288 Glycoproteins Proteins 0.000 title claims abstract description 7
102000003886 Glycoproteins Human genes 0.000 title claims abstract description 7
229940124725 herpes simplex vaccine Drugs 0.000 title 1
239000000203 mixture Substances 0.000 claims abstract description 66
238000009472 formulation Methods 0.000 claims abstract description 58
229960005486 vaccine Drugs 0.000 claims abstract description 36
230000001900 immune effect Effects 0.000 claims abstract description 8
208000009889 Herpes Simplex Diseases 0.000 claims abstract description 7
239000012634 fragment Substances 0.000 claims abstract description 7
229940037003 alum Drugs 0.000 claims description 54
239000007764 o/w emulsion Substances 0.000 claims description 21
208000015181 infectious disease Diseases 0.000 claims description 18
102100022717 Atypical chemokine receptor 1 Human genes 0.000 claims description 11
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 claims description 11
102000004169 proteins and genes Human genes 0.000 claims description 9
108090000623 proteins and genes Proteins 0.000 claims description 9
238000000034 method Methods 0.000 claims description 7
101900228213 Human herpesvirus 2 Envelope glycoprotein D Proteins 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
238000002156 mixing Methods 0.000 claims description 3
210000004899 c-terminal region Anatomy 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims description 2
238000011282 treatment Methods 0.000 claims description 2
239000003814 drug Substances 0.000 claims 2
230000003053 immunization Effects 0.000 description 27
238000002649 immunization Methods 0.000 description 27
241000701074 Human alphaherpesvirus 2 Species 0.000 description 22
239000002671 adjuvant Substances 0.000 description 21
230000003472 neutralizing effect Effects 0.000 description 21
238000002965 ELISA Methods 0.000 description 20
241001465754 Metazoa Species 0.000 description 20
201000010099 disease Diseases 0.000 description 20
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
241000700198 Cavia Species 0.000 description 19
239000000427 antigen Substances 0.000 description 19
102000036639 antigens Human genes 0.000 description 19
108091007433 antigens Proteins 0.000 description 19
208000027930 type IV hypersensitivity disease Diseases 0.000 description 19
230000000306 recurrent effect Effects 0.000 description 18
206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 17
230000005951 type IV hypersensitivity Effects 0.000 description 17
241000700584 Simplexvirus Species 0.000 description 15
230000003902 lesion Effects 0.000 description 15
230000000694 effects Effects 0.000 description 14
238000002474 experimental method Methods 0.000 description 13
238000002255 vaccination Methods 0.000 description 13
210000004027 cell Anatomy 0.000 description 12
238000010790 dilution Methods 0.000 description 11
239000012895 dilution Substances 0.000 description 11
230000004044 response Effects 0.000 description 10
238000005406 washing Methods 0.000 description 10
241000700199 Cavia porcellus Species 0.000 description 9
241000282693 Cercopithecidae Species 0.000 description 9
239000000872 buffer Substances 0.000 description 9
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 9
230000006698 induction Effects 0.000 description 9
239000002953 phosphate buffered saline Substances 0.000 description 9
238000002360 preparation method Methods 0.000 description 9
230000004224 protection Effects 0.000 description 9
230000003612 virological effect Effects 0.000 description 9
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
238000003556 assay Methods 0.000 description 8
206010040882 skin lesion Diseases 0.000 description 8
231100000444 skin lesion Toxicity 0.000 description 8
206010015150 Erythema Diseases 0.000 description 7
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 7
229910021502 aluminium hydroxide Inorganic materials 0.000 description 7
230000028993 immune response Effects 0.000 description 7
230000005847 immunogenicity Effects 0.000 description 7
230000001404 mediated effect Effects 0.000 description 7
238000006386 neutralization reaction Methods 0.000 description 7
235000018102 proteins Nutrition 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 7
241000282552 Chlorocebus aethiops Species 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
230000001939 inductive effect Effects 0.000 description 6
230000001681 protective effect Effects 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000005867 T cell response Effects 0.000 description 5
239000012636 effector Substances 0.000 description 5
210000003162 effector t lymphocyte Anatomy 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
238000002347 injection Methods 0.000 description 5
239000007924 injection Substances 0.000 description 5
239000002609 medium Substances 0.000 description 5
230000003389 potentiating effect Effects 0.000 description 5
208000037920 primary disease Diseases 0.000 description 5
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
241000282560 Macaca mulatta Species 0.000 description 4
241000700605 Viruses Species 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
150000001413 amino acids Chemical class 0.000 description 4
230000005875 antibody response Effects 0.000 description 4
239000000839 emulsion Substances 0.000 description 4
231100000321 erythema Toxicity 0.000 description 4
210000004392 genitalia Anatomy 0.000 description 4
230000004727 humoral immunity Effects 0.000 description 4
230000036039 immunity Effects 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
239000000243 solution Substances 0.000 description 4
230000024932 T cell mediated immunity Effects 0.000 description 3
238000002835 absorbance Methods 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000011554 guinea pig model Methods 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
229940032094 squalane Drugs 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
230000029812 viral genome replication Effects 0.000 description 3
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
208000001688 Herpes Genitalis Diseases 0.000 description 2
241000700588 Human alphaherpesvirus 1 Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
241000288906 Primates Species 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
210000001015 abdomen Anatomy 0.000 description 2
239000008365 aqueous carrier Substances 0.000 description 2
229960002685 biotin Drugs 0.000 description 2
235000020958 biotin Nutrition 0.000 description 2
239000011616 biotin Substances 0.000 description 2
239000013553 cell monolayer Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000004590 computer program Methods 0.000 description 2
238000001514 detection method Methods 0.000 description 2
201000004946 genital herpes Diseases 0.000 description 2
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
238000011597 hartley guinea pig Methods 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
230000008348 humoral response Effects 0.000 description 2
230000002480 immunoprotective effect Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000002941 microtiter virus yield reduction assay Methods 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
238000000611 regression analysis Methods 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
208000030090 Acute Disease Diseases 0.000 description 1
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
101710121417 Envelope glycoprotein Proteins 0.000 description 1
206010048461 Genital infection Diseases 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
208000004898 Herpes Labialis Diseases 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
102100034349 Integrase Human genes 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
208000032420 Latent Infection Diseases 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010067152 Oral herpes Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
230000000240 adjuvant effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
229960003942 amphotericin b Drugs 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000003622 anti-hsv Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
235000010410 calcium alginate Nutrition 0.000 description 1
239000000648 calcium alginate Substances 0.000 description 1
229960002681 calcium alginate Drugs 0.000 description 1
OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
244000309466 calf Species 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
208000037771 disease arising from reactivation of latent virus Diseases 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
230000004927 fusion Effects 0.000 description 1
210000000609 ganglia Anatomy 0.000 description 1
230000028996 humoral immune response Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
229960001438 immunostimulant agent Drugs 0.000 description 1
239000003022 immunostimulating agent Substances 0.000 description 1
230000003308 immunostimulating effect Effects 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000002803 maceration Methods 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000013160 medical therapy Methods 0.000 description 1
230000017074 necrotic cell death Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
238000011002 quantification Methods 0.000 description 1
210000005000 reproductive tract Anatomy 0.000 description 1
238000011160 research Methods 0.000 description 1
238000013207 serial dilution Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
229940031439 squalene Drugs 0.000 description 1
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
229940038774 squalene oil Drugs 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
229940031626 subunit vaccine Drugs 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000008399 tap water Substances 0.000 description 1
235000020679 tap water Nutrition 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
238000004448 titration Methods 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000007501 viral attachment Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
- C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Virology (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Mycology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Communicable Diseases (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Engineering & Computer Science (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

APAP/P/1992/000368A 1991-03-21 1992-03-20 Herpes simplex vaccine comprising HSV Glycoprotein gD and 3 deacylated mono-phosphoryl lipid A. AP298A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB9105992A GB9105992D0 (en)	1991-03-21	1991-03-21	Vaccine

Publications (2)

Publication Number	Publication Date
AP9200368A0 AP9200368A0 (en)	1992-04-30
AP298A true AP298A (en)	1994-01-14

Family

ID=10691946

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1992/000368A AP298A (en)	1991-03-21	1992-03-20	Herpes simplex vaccine comprising HSV Glycoprotein gD and 3 deacylated mono-phosphoryl lipid A.

Country Status (33)

Country	Link
US (1)	US6027730A (fr)
EP (1)	EP0576478B2 (fr)
JP (1)	JP3530526B2 (fr)
KR (1)	KR100224329B1 (fr)
CN (2)	CN1058191C (fr)
AP (1)	AP298A (fr)
AT (1)	ATE129160T1 (fr)
AU (1)	AU650521B2 (fr)
BR (1)	BR9205745A (fr)
CA (1)	CA2106492C (fr)
CY (1)	CY1936A (fr)
CZ (1)	CZ280505B6 (fr)
DE (1)	DE69205566T3 (fr)
DK (1)	DK0576478T4 (fr)
ES (1)	ES2081102T5 (fr)
FI (1)	FI107881B (fr)
GB (1)	GB9105992D0 (fr)
GR (1)	GR3017884T3 (fr)
HU (1)	HU218025B (fr)
IE (1)	IE69560B1 (fr)
IL (1)	IL101290A (fr)
MA (1)	MA22471A1 (fr)
MX (1)	MX9201245A (fr)
MY (1)	MY110086A (fr)
NO (1)	NO307499B1 (fr)
NZ (1)	NZ242057A (fr)
PL (1)	PL170059B1 (fr)
PT (1)	PT100262B (fr)
SA (1)	SA92120459B1 (fr)
SK (1)	SK279190B6 (fr)
WO (1)	WO1992016231A1 (fr)
YU (1)	YU28392A (fr)
ZA (1)	ZA922011B (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9105992D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccine
US6197311B1 (en)	1991-07-25	2001-03-06	Idec Pharmaceuticals Corporation	Induction of cytotoxic T-lymphocyte responses
GB9202933D0 (en) *	1992-02-12	1992-03-25	Smithkline Beecham Biolog	Vaccines
US6620414B2 (en)	1992-03-27	2003-09-16	Smithkline Beecham Biologicals (S.A.)	Hepatitis vaccines containing 3-0-deacylated monophoshoryl lipid A
WO1994019013A1 (fr) *	1993-02-19	1994-09-01	Smithkline Beecham Corporation	Compositions de vaccin contre la grippe, contenant un lipide a de monophosphoryle desacyle en position 3-o
EP0689454B2 (fr) *	1993-03-23	2005-02-23	SMITHKLINE BEECHAM BIOLOGICALS s.a.	Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle
DE69426077T3 (de) *	1993-05-25	2004-09-02	Wyeth Holdings Corp.	Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus
GB9326253D0 (en) *	1993-12-23	1994-02-23	Smithkline Beecham Biolog	Vaccines
ES2197217T3 (es) *	1994-12-28	2004-01-01	University Of Kentucky Research Foundation	Anticuerpo 3h1 monoclonal anti-id-murino.
US6949244B1 (en)	1995-12-20	2005-09-27	The Board Of Trustees Of The University Of Kentucky	Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
US20020041872A1 (en)	1996-04-12	2002-04-11	Malaya Chatterjee	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6235280B1 (en)	1996-04-12	2001-05-22	Malaya Chatterjee	Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
US6468782B1 (en)	1996-12-05	2002-10-22	Quadrant Healthcare (Uk) Limited	Methods of preserving prokaryotic cells and compositions obtained thereby
US6274143B1 (en)	1997-06-13	2001-08-14	Malaya Chatterjee	Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
US6355244B1 (en)	1997-11-17	2002-03-12	University Of Kentucky Research Foundation	Methods and compositions for the treatment of psoriasis
GB9819898D0 (en) *	1998-09-11	1998-11-04	Smithkline Beecham Plc	New vaccine and method of use
US6692752B1 (en) *	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
DE122007000087I1 (de)	1998-10-16	2008-03-27	Glaxosmithkline Biolog Sa	Adjuvanzsysteme und impfstoffe
US7026155B2 (en)	1999-02-02	2006-04-11	Regents Of The University Of California	Method of reducing bacterial proliferation
EP1104767A1 (fr)	1999-11-30	2001-06-06	Stichting Dienst Landbouwkundig Onderzoek	Dérivés de mono- et disaccharides contenant esters d'acides gras et esters de sulfate
US9273326B2 (en)	2004-04-30	2016-03-01	The Brigham And Women's Hospital, Inc.	Tetracycline-regulated gene expression in HSV-1 vectors
JP2008513406A (ja)	2004-09-22	2008-05-01	グラクソスミスクラインバイオロジカルズソシエテアノニム	免疫原性組成物
TW200700079A (en)	2005-03-23	2007-01-01	Glaxosmithkline Biolog Sa	Composition
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
CN103251940A (zh)	2005-12-22	2013-08-21	葛兰素史密丝克莱恩生物有限公司	疫苗
EP1998802A2 (fr)	2006-03-30	2008-12-10	GlaxoSmithKline Biologicals S.A.	Composition immunogène
MX2009000660A (es)	2006-07-17	2009-04-08	Glaxosmithkline Biolog Sa	Vacuna de influenza.
US20090181078A1 (en) *	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
HUE036180T2 (hu)	2006-09-26	2018-06-28	Infectious Disease Res Inst	Szintetikus adjuvánst tartalmazó vakcina készítmény
US9452209B2 (en)	2007-04-20	2016-09-27	Glaxosmithkline Biologicals Sa	Influenza vaccine
MX2009013949A (es)	2007-06-26	2010-05-24	Glaxosmithkline Biolog Sa	Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
AU2010249330B2 (en)	2009-05-22	2015-11-05	Genocea Biosciences Inc.	Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
HUE031051T2 (en) *	2009-06-05	2017-06-28	Infectious Disease Res Inst	Synthetic glycopyranosyl lipid adjuvant and vaccine compositions containing it
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
US8809047B2 (en) *	2009-12-21	2014-08-19	The Brigham And Women's Hospital, Inc.	Herpes simplex virus vaccines
AU2011336894B2 (en)	2010-11-24	2016-11-17	Genocea Biosciences, Inc.	Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
EP2683402B1 (fr) *	2011-03-11	2020-06-24	Turnstone Limited Partnership	Méthode de vaccination faisant intervenir un inhibiteur d'histone désacétylase
EP3632463A1 (fr)	2011-04-08	2020-04-08	Immune Design Corp.	Compositions immunogènes et leurs procédés d'utilisation pour induire des réponses immunitaires humorales et cellulaires
WO2013028738A1 (fr)	2011-08-22	2013-02-28	Nanobio Corporation	Vaccin contre le virus de l'herpès simplex sous forme de nanoémulsion
AU2012340712B2 (en)	2011-11-23	2017-09-14	Genocea Biosciences, Inc.	Nucleic acid vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
SI2850431T1 (en)	2012-05-16	2018-08-31	Immune Design Corp.	Vaccines for hsv-2
DK2941269T3 (da)	2013-01-07	2021-01-11	Mucosal Vaccine Tech Llc	Terapeutiske vacciner til behandling af herpes simplex-virus type 2-infektioner
EP2986303B1 (fr)	2013-04-18	2020-02-26	Immune Design Corp.	Monothérapie par gla pour une utilisation dans le traitement du cancer
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
JP2019537555A (ja)	2016-09-28	2019-12-26	ジェノセアバイオサイエンシーズ，インコーポレイテッド	ヘルペスを処置するための方法および組成物
WO2019152821A1 (fr)	2018-02-05	2019-08-08	The Brigham And Women's Hospital, Inc.	Virus de l'herpès simplex 2 recombinant exprimant des antigènes de glycoprotéine b et d
CA3208643A1 (fr)	2021-01-18	2022-07-21	Conserv Bioscience Limited	Compositions immunogenes de coronavirus, methodes et utilisations de celles-ci

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988002634A1 (fr) *	1986-10-20	1988-04-21	Chiron Corporation	Vaccin utilise pour le traitement therapeutique de hsv
GB2220211A (en) *	1988-06-29	1990-01-04	Ribi Immunochem Research Inc	Modified lipopolysaccharides

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4372945A (en) *	1979-11-13	1983-02-08	Likhite Vilas V	Antigen compounds
IL61904A (en) *	1981-01-13	1985-07-31	Yeda Res & Dev	Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
US5110587A (en) *	1981-12-24	1992-05-05	Health Research, Incorporated	Immunogenic composition comprising synthetically modified vaccinia virus
US4762708A (en) *	1982-02-18	1988-08-09	University Patents, Inc.	Materials and methods for herpes simplex virus vaccination
US5149660A (en) *	1982-02-18	1992-09-22	University Patents, Inc.	Diagnostic reagents relating to herpes simplex virus
NZ209308A (en) *	1983-08-30	1991-08-27	Genentech Inc	Vaccine against hsv involving a truncated membrane-free derivative of a membrane-bound protein
US5171568A (en) *	1984-04-06	1992-12-15	Chiron Corporation	Recombinant herpes simplex gb-gd vaccine
US5244792A (en) *	1984-04-06	1993-09-14	Chiron Corporation	Expression of recombinant glyoprotein B from herpes simplex virus
US4877611A (en) *	1986-04-15	1989-10-31	Ribi Immunochem Research Inc.	Vaccine containing tumor antigens and adjuvants
US5554372A (en) *	1986-09-22	1996-09-10	Emory University	Methods and vaccines comprising surface-active copolymers
US5149529A (en) *	1988-04-08	1992-09-22	Board Of Trustees Of Leland Chiron Corporation	Compositions and treatment for herpes simplex
NZ230424A (en) *	1988-08-25	1992-05-26	Liposome Co Inc	Liposomal composition comprising an externally disposed antigen
JP2955314B2 (ja) *	1988-10-27	1999-10-04	リージェンツ・オブ・ザ・ユニバーシティー・オブ・ミネソタ	Ｉｌ―２含有リポソーム免疫アジュバント
US5597573A (en) *	1989-05-04	1997-01-28	Igen, Inc.	Lipid-A analogs: new monosaccharide and disaccharide intermediates for eliciting therapeutic antibodies and for antitumor and antiviral activities
US5158939A (en) *	1989-07-21	1992-10-27	Wisconsin Alumni Research Foundation	Method of stimulating the immune systems of animals and compositions useful therefor
FI920131A0 (fi) *	1989-07-14	1992-01-13	Praxis Biolog Inc	Cytokin- och hormonbaerare foer konjugatvaccin.
CA2088246A1 (fr) *	1990-08-01	1992-02-02	Dennis J. O'callaghan	Gene codant la glycoproteine d du virus herpetique equin de type i, son produit genique, et anticorps de cette glycoproteine et leurs utilisations
JP3005292B2 (ja) *	1990-08-02	2000-01-31	カイロンコーポレイション	単純ヘルペスウィルスのｖｐ１６のワクチン
GB9106048D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccines
US5166173A (en) *	1991-01-29	1992-11-24	Genelabs Incorporated	Method of treating herpes simplex virus infection
US5196452A (en) *	1991-01-29	1993-03-23	Genelabs Incorporated	Macrocyclic anti-viral compound and method
GB9105992D0 (en) *	1991-03-21	1991-05-08	Smithkline Beecham Biolog	Vaccine
MA22842A1 (fr) *	1992-03-27	1993-10-01	Smithkline Beecham Biolog	Procede de preparation de compositions de vaccin.
NZ253137A (en) *	1992-06-25	1996-08-27	Smithkline Beecham Biolog	Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
WO1994019013A1 (fr) *	1993-02-19	1994-09-01	Smithkline Beecham Corporation	Compositions de vaccin contre la grippe, contenant un lipide a de monophosphoryle desacyle en position 3-o
EP0689454B2 (fr) *	1993-03-23	2005-02-23	SMITHKLINE BEECHAM BIOLOGICALS s.a.	Compositions vaccinales renfermant le lipide a monophosphorylique 3-o desacetyle
DE69426077T3 (de) *	1993-05-25	2004-09-02	Wyeth Holdings Corp.	Adjuvantien für impfstoffe gegen das respiratorische synzitialvirus

1991
- 1991-03-21 GB GB9105992A patent/GB9105992D0/en active Pending
1992
- 1992-03-17 AU AU13657/92A patent/AU650521B2/en not_active Expired
- 1992-03-17 PL PL92300617A patent/PL170059B1/pl unknown
- 1992-03-17 ES ES92906441T patent/ES2081102T5/es not_active Expired - Lifetime
- 1992-03-17 CA CA 2106492 patent/CA2106492C/fr not_active Expired - Lifetime
- 1992-03-17 AT AT92906441T patent/ATE129160T1/de active
- 1992-03-17 WO PCT/EP1992/000592 patent/WO1992016231A1/fr not_active Ceased
- 1992-03-17 CY CY193692A patent/CY1936A/xx unknown
- 1992-03-17 JP JP50598492A patent/JP3530526B2/ja not_active Expired - Lifetime
- 1992-03-17 SK SK946-93A patent/SK279190B6/sk unknown
- 1992-03-17 KR KR1019930702835A patent/KR100224329B1/ko not_active Expired - Lifetime
- 1992-03-17 EP EP19920906441 patent/EP0576478B2/fr not_active Expired - Lifetime
- 1992-03-17 HU HU9302645A patent/HU218025B/hu unknown
- 1992-03-17 BR BR9205745A patent/BR9205745A/pt not_active Application Discontinuation
- 1992-03-17 DK DK92906441T patent/DK0576478T4/da active
- 1992-03-17 DE DE69205566T patent/DE69205566T3/de not_active Expired - Lifetime
- 1992-03-17 CZ CS931958A patent/CZ280505B6/cs not_active IP Right Cessation
- 1992-03-18 MY MYPI92000448A patent/MY110086A/en unknown
- 1992-03-19 ZA ZA922011A patent/ZA922011B/xx unknown
- 1992-03-19 IE IE920881A patent/IE69560B1/en not_active IP Right Cessation
- 1992-03-19 IL IL10129092A patent/IL101290A/en not_active IP Right Cessation
- 1992-03-19 PT PT100262A patent/PT100262B/pt not_active IP Right Cessation
- 1992-03-19 NZ NZ242057A patent/NZ242057A/en not_active IP Right Cessation
- 1992-03-19 CN CN92102950A patent/CN1058191C/zh not_active Expired - Lifetime
- 1992-03-19 MA MA22760A patent/MA22471A1/fr unknown
- 1992-03-20 MX MX9201245A patent/MX9201245A/es unknown
- 1992-03-20 YU YU28392A patent/YU28392A/sh unknown
- 1992-03-20 AP APAP/P/1992/000368A patent/AP298A/en active
- 1992-04-21 SA SA92120459A patent/SA92120459B1/ar unknown
1993
- 1993-09-20 NO NO933343A patent/NO307499B1/no not_active IP Right Cessation
- 1993-09-21 FI FI934134A patent/FI107881B/fi not_active IP Right Cessation
1994
- 1994-09-09 US US08/303,542 patent/US6027730A/en not_active Expired - Lifetime
1995
- 1995-10-25 GR GR950402992T patent/GR3017884T3/el unknown
1998
- 1998-01-05 CN CN98103933A patent/CN1101226C/zh not_active Expired - Lifetime

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988002634A1 (fr) *	1986-10-20	1988-04-21	Chiron Corporation	Vaccin utilise pour le traitement therapeutique de hsv
GB2220211A (en) *	1988-06-29	1990-01-04	Ribi Immunochem Research Inc	Modified lipopolysaccharides

Also Published As

Publication number	Publication date
PT100262A (pt)	1993-06-30
CY1936A (en)	1992-03-17
EP0576478B2 (fr)	2001-04-18
HU9302645D0 (en)	1994-01-28
JP3530526B2 (ja)	2004-05-24
AU650521B2 (en)	1994-06-23
CN1101226C (zh)	2003-02-12
PL170059B1 (pl)	1996-10-31
JPH06505727A (ja)	1994-06-30
EP0576478B1 (fr)	1995-10-18
IL101290A (en)	1996-07-23
NO933343L (no)	1993-09-20
ES2081102T3 (es)	1996-02-16
BR9205745A (pt)	1994-10-18
SK94693A3 (en)	1994-05-11
HUT67052A (en)	1995-01-30
MY110086A (en)	1997-12-31
ATE129160T1 (de)	1995-11-15
NO307499B1 (no)	2000-04-17
KR100224329B1 (ko)	1999-10-15
SK279190B6 (sk)	1998-07-08
YU28392A (sh)	1994-11-15
IL101290A0 (en)	1992-11-15
DE69205566T3 (de)	2002-09-05
GB9105992D0 (en)	1991-05-08
ZA922011B (en)	1993-01-27
NO933343D0 (no)	1993-09-20
DE69205566D1 (en)	1995-11-23
FI107881B (fi)	2001-10-31
CA2106492A1 (fr)	1992-09-22
DE69205566T2 (de)	1996-04-18
CZ195893A3 (en)	1994-07-13
CN1065997A (zh)	1992-11-11
EP0576478A1 (fr)	1994-01-05
IE69560B1 (en)	1996-10-02
FI934134A0 (fi)	1993-09-21
HK1004525A1 (en)	1998-11-27
SA92120459B1 (ar)	2005-06-14
CZ280505B6 (cs)	1996-02-14
NZ242057A (en)	1993-12-23
WO1992016231A1 (fr)	1992-10-01
DK0576478T4 (da)	2001-07-23
CN1058191C (zh)	2000-11-08
GR3017884T3 (en)	1996-01-31
MX9201245A (es)	1992-10-01
IE920881A1 (en)	1992-09-23
HU218025B (hu)	2000-05-28
AU1365792A (en)	1992-10-21
CA2106492C (fr)	2003-12-09
FI934134L (fi)	1993-09-21
CN1201692A (zh)	1998-12-16
AP9200368A0 (en)	1992-04-30
PT100262B (pt)	2001-05-31
US6027730A (en)	2000-02-22
MA22471A1 (fr)	1992-10-01
DK0576478T3 (da)	1995-12-04
ES2081102T5 (es)	2001-09-01

Publication	Publication Date	Title
AP298A (en)	1994-01-14	Herpes simplex vaccine comprising HSV Glycoprotein gD and 3 deacylated mono-phosphoryl lipid A.
JP4510283B2 (ja)	2010-07-21	併合ワクチン組成物
CA2217178C (fr)	2009-09-29	Vaccins contenant une saponine ainsi qu'un sterol
US7220551B2 (en)	2007-05-22	Composition
US7371390B2 (en)	2008-05-13	Vaccine against HBV and HPV
HK1004525B (en)	1998-11-27	Herpes simplex vaccine comprising hsv glycoprotein gd and 3 deacylated monophosphoryl lipid a
MXPA00008817A (en)	2001-07-09	Combined vaccine compositions
CZ20003284A3 (cs)	2001-02-14	Vakcína
BRPI0017420B1 (pt)	2020-10-06	Composição de vacina, hpv 16 l1 e hpv 18 l1 vpl